罗格列酮联合二甲双胍治疗初诊2型糖尿病的疗效观察

目的：罗格列酮（RGZ）联合二甲双胍治疗初诊2型糖尿病（T2DM）的临床疗效和安全性。方法：40例初诊2型糖尿病联用罗格列酮和二甲双胍进行12周的治疗,测定治疗前后空腹血糖（FBG）、餐后2小时血糖（PPG）、糖化血红蛋白（HbA1c）、胰岛素、C-肽、甘油三脂、体重指数（BMI）,胰岛素抵抗指数（IR）、血常规、肝、肾功能等。结果：治疗前后对照,空腹及餐后血糖、胰岛素、甘油三脂I、RI降低,具有显著差异性（P〈0.001）,体重指数变化不大（P〉0.05）,未发生肝肾功能损害。结论：罗格列酮联合二甲双胍治疗2型糖尿病,明显改善胰岛素抵抗,降糖疗效确切。

Therapeutic Effect of the Co-administrated Metformin and Rosiglitazone in Treatment of Newly Diagnosed Type 2 Diabetes Mellitos

Objective： To study the therapeutic effect and safty of co-administ rated metformin and rosiglitazone in the t reatment of newly diagnosed type 2 Diabetes Mellitus （T2DM）. Methods： forty newly-diagnosed T2DM patients had been co-administrated by Metformin and Rosiglitazone for 12 weeks. FBG, 2h-PG, HbA1C, insulin, C-peptide, TG, body mass index （BMI）, HOMA-IR, blood routine, hepatic function and renal function was calculated before and after treatment. Results： FBG, 2h-PG, insulin, HbA1C and insulin resistance were effectively decreased （P〈0. 001）, hut there was no difference on BMI after treatment. There were no hepatic and renal damage. Conclusion： Treatment of co-administrated Metformin and Rosiglitazone can improve insulin resistance, and it can definitely decrease blood glucose.